Literature DB >> 16490134

Methicillin-resistant Staphylococcus aureus in the community in West Essex.

S Millership1, J Harris, N Batchelor.   

Abstract

The study was undertaken in response to local concerns of a rising number of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections. All patients resident in the community in Essex at the time of diagnosis with a first isolate of MRSA between 1994 and 2001 identified by the diagnostic microbiology laboratory were included. Although the annual incidence rose throughout the study period the majority of those with MRSA (82%) had had hospital contact within the last 5 years. The subset of patients without hospital contact had a median age of 79.5 years, 63% were female and 32% were residents of care homes. Carriage in this population was detected for up to 41 months post-diagnosis. Neither antibiogram nor clinical presentation distinguished these isolates from local hospital-acquired strains.

Entities:  

Mesh:

Year:  2006        PMID: 16490134      PMCID: PMC2870401          DOI: 10.1017/S0950268805005091

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  17 in total

1.  Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections--Los Angeles County, California, 2002-2003.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2003-02-07       Impact factor: 17.586

2.  Nottingham Staphylococcus aureus population study: prevalence of MRSA among elderly people in the community.

Authors:  Hajo Grundmann; Adriana Tami; Satoshi Hori; Muhammad Halwani; Richard Slack
Journal:  BMJ       Date:  2002-06-08

3.  MRSA in nursing homes in the Netherlands 1989 to 1998: a developing reservoir?

Authors:  W Goettsch; E Geubbels; W Wannet; M.G.R. Hendrix; J.H.T. Wagenvoort; A.J De Neeling
Journal:  Euro Surveill       Date:  2000-03

4.  Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus — Minnesota and North Dakota, 1997-1999.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1999-08-20       Impact factor: 17.586

5.  Emergence of methicillin-resistant Staphylococcus aureus with Panton-Valentine leukocidin genes in central Europe.

Authors:  W Witte; C Braulke; C Cuny; B Strommenger; G Werner; D Heuck; U Jappe; C Wendt; H-J Linde; D Harmsen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-01       Impact factor: 3.267

6.  Methicillin-resistant Staphylococcus aureus (MRSA): a community-based prevalence survey.

Authors:  L Abudu; I Blair; A Fraise; K K Cheng
Journal:  Epidemiol Infect       Date:  2001-06       Impact factor: 2.451

7.  The prevalence of methicillin-resistant staphylococcus aureus among the residents of six nursing homes for the elderly.

Authors:  N R O'Sullivan; C T Keane
Journal:  J Hosp Infect       Date:  2000-08       Impact factor: 3.926

8.  Prevalence of methicillin-resistant and methicillin-susceptible Staphylococcus aureus in the community.

Authors:  B Shopsin; B Mathema; J Martinez; E Ha; M L Campo; A Fierman; K Krasinski; J Kornblum; P Alcabes; M Waddington; M Riehman; B N Kreiswirth
Journal:  J Infect Dis       Date:  2000-07-06       Impact factor: 5.226

9.  [Inquiry into the incidence of nosocomial infections and evaluation of the transmission of methicillin-resistant Staphylococcus aureus in an orthopedic surgical unit].

Authors:  C Zulian; P Descamps; B Samyn; J P Lemerle; O Gaillot
Journal:  Pathol Biol (Paris)       Date:  1999-05

10.  Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors.

Authors:  Cassandra D Salgado; Barry M Farr; David P Calfee
Journal:  Clin Infect Dis       Date:  2003-01-03       Impact factor: 9.079

View more
  1 in total

1.  Considering the precautionary principle and its application to MRSA and SARS-CoV-2 as emerging novel pathogens of their time.

Authors:  Joanna Harris; Hazel Maxwell; Susan Dodds
Journal:  Infect Dis Health       Date:  2022-09-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.